Releases - Allenex AB

View:
 

Found press releases

 

ONCOlog has filed for bankruptcy

5/8/2013 6:46 AM EST
Since the autumn of 2012, the Board of ONCOlog has worked to find buyers for the sale of the entire company or its assets. However, these efforts have not been successful and the ONCOlog Board has therefore not seen any alternative left but to apply for the company to be declared bankrupt.
Allenex owns 14.9% of ONCOlog, but has since mid-2011 changed its focus to include the transplantation area only. Allenex has...

Allenex enter agreement on conditions for loan refinancing

4/25/2013 2:33 AM EST
Allenex AB enters agreement for refinancing of existing loans according to the following:

As stated earlier, Allenex and other companies within the group have a bank loan of 30 msek and a convertible 31 msek, due for payment June 30th2013. A refinancing agreement is now ready. The above loans and another bank loan of 27 msek are paid, financed by new loans of 90 msek. The new loans are provided by Allenex main bank...

Allenex jan-dec: 112,7 msek (98,7) net sales

2/21/2013 8:01 AM EST
For the fourth quarter October - December

· Net sales for the quarter amounted to SEK 27.4 million (27.5). Sales were impacted by a negative currency effect of SEK 1.2 million compared to the same period last year. Adjusted for currency effects, the growth rate was 4 percent.
· Operating income (EBIT) for the quarter was SEK 0.6 million (-76.0), with currency effects having a negative impact of SEK 1.4 million on...

US breakthrough order for Allenex with SBT Resolver™

2/19/2013 5:15 AM EST
A leading United States based HLA laboratory has chosen Allenex´s US distribution company Olerup Inc as their partner for the delivery of sequence based HLA tissue typing, SBT. This top tier immunogenetics laboratory has evaluated and validated SBT Resolver™ from the Allenex partner Conexio Genomics. The lab committed to the use of SBT Resolver™, and has already subsequently placed an initial order, which also...

Allenex receives part of €2.6M EU grant in collaboration with EUROSTAM

2/1/2013 4:16 AM EST
Allenex announces that Allenex group company AbSorber, together with EUROSTAM, a consortium of European Transplant Centers, has been supported by a € 2.6 million grant as part of the European Commission 7th framework programme (FP7). This is part of an ongoing Europe-wide strategy to enhance transplantation of highly sensitized patients where risk of complication is high due to genetic mismatches. The main objective...

Allenex jan-sep: 85,3 msek (71,2) net sales

11/20/2012 10:01 AM EST
Allenex interim report JANUARY – SEPTEMBER 2012
For the third quarter July - September

· Net sales for the quarter amounted to SEK 26.7 million (26.3), corresponding to a 1.5 percent increase compared to the same period last year. Sales were impacted by a negative currency effect of SEK 1.4 million compared to the year before, and the growth rate adjusted for currency effects is 6.8 percent.
· Operating...
Allenex Lab Pic 1
 

24 MSEK contract won in France

9/27/2012 2:46 AM EST
The French blood center organization EFS has in this tender chosen HLA typing products from Allenex. After a central evaluation, it is clear that the 17 transplant laboratories that are part of EFS during the next four years will use typing products from Allenex subsidiary Olerup SSP.
This is the first time that SSP typing products are acquired on a national level purchasing agreement on the to Allenex...

Allenex jan-jun: 58,6 msek (44,9) net sales

8/28/2012 8:02 AM EST
Interim report JANUARY – JUNE 2012
For the second quarter April - June

· Net sales for the quarter were SEK 28.7 million (24.4), an increase of 17.6 percent compared to the same period last year. (Olerup GmbH became a part of the group on June 1, 2011).
· Operating income (EBIT) for the quarter was SEK 3.1 million (-8.7).
· Operating margin for the quarter was 11 percent (-35).
· Earnings after tax for the...

University of Miami initiates clinical trial of XM-ONE®

6/8/2012 5:02 AM EST
The transplantation unit at Jackson Memorial Hospital and the University of Miami, FL, USA has entered into a research project with the Allenex group company AbSorber. The project is a pilot study evaluating the endothelial cell cross match XM-ONE® in their Living Donor program. University of Miami will investigate if antibodies detected by XM-ONE® will affect the outcome for the individual patient, in pre- and...

University of Miami initiates clinical trial of XM-ONE®

6/7/2012 5:16 AM EST
The transplantation unit at Jackson Memorial Hospital and the University of Miami, FL, USA has entered into a research project with the Allenex group company AbSorber. The project is a pilot study evaluating the endothelial cell cross match XM-ONE® in their Living Donor program. University of Miami will investigate if antibodies detected by XM-ONE® will affect the outcome for the individual patient, in pre- and...

Allenex AB

RSS

LinkMed, in collaboration with innovators, develops new life science companies. By contributing entrepreneurship and capital, LinkMed has created a portfolio of eleven companies, six in biotechnology and five in medical ...

View more


  CONTACT